Title:The Emerging Role of LncRNA FENDRR in Multiple Cancers: A
Review
Volume: 23
Issue: 7
Author(s): Hoda Fazaeli, Azar Sheikholeslami, Fatemeh Ghasemian, Elaheh Amini and Mohsen Sheykhhasan*
Affiliation:
- Department of Mesenchymal Stem Cells, Academic Center for Education, Culture and Research (ACECR),
Qom Branch, Qom, Iran
- Department of Molecular Medicine and Genetics, Research Center for Molecular Medicine, Hamadan
University of Medical Sciences, Hamadan, Iran
Keywords:
FENDRR, lncRNAs, cancer, regulatory mechanism, biomarker, RNAs.
Abstract: Long noncoding RNAs (lncRNAs) are prominent as crucial regulators of tumor
establishment and are repeatedly dysregulated in multiple cancers. Therefore, lncRNAs
have been identified to play an essential function in carcinogenesis and progression of
cancer at genetic and epigenetic levels. FENDRR (fetal-lethal noncoding developmental
regulatory RNA) as a LncRNA is a hallmark of various malignancies. FENDRR is crucial
for multiple organs' development, such as the lung and heart. The effects of FENDRR
under signaling pathways in different cancers have been identified. In addition, it has
been verified that FENDRR can affect the development and progression of various
cancers. In addition, FENDRR expression has been associated with epigenetic
regulation of target genes participating in tumor immunity. Furthermore, FENDRR
downregulation was observed in various types of cancers, including colorectal cancer,
gastric cancer, pancreatic cancer, cholangiocarcinoma, liver cancer, gallbladder cancer,
lung cancer, breast cancer, endometrial cancer, prostate cancer, chronic myeloid
leukemia, osteosarcoma, and cutaneous malignant melanoma cells. Here, we review the
biological functions and molecular mechanisms of FENDRR in several cancers, and we
will discuss its potential as a cancer biomarker and as a probable option for cancer
treatment.
